Articles published by GlobeNewswire

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Tickers AVAI CSE:GOH GHVNF ONCY TSX-V:VPT VPTDF

December 06, 2025

Anthony Constantino’s ‘Thank You President Trump’ Album Release To Light Up Fontainebleau LIV Tonight; Hit song “Fight” has over 4 million views in 5 days

Tickers AGL

December 06, 2025

From Sticker Mule

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

December 06, 2025

From Prelude Therapeutics, Incorporated

BLUE OWL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Blue Owl Capital, Inc. and Encourages Investors to Contact the Firm

Tickers PRLD

December 06, 2025

CEPTON URGENT ALERT: Bragar Eagel & Squire, P.C. Reminds Cepton Stockholders of Upcoming December 8th Lead Plaintiff Deadline

December 06, 2025

MAREX URGENT DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Marex Stockholders to Contact the Firm Before December 8th Deadline

December 06, 2025

ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights

Tickers MRX

December 06, 2025

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB

Tickers ATYR

December 06, 2025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Tickers STUB

December 06, 2025

From Adaptive Biotechnologies

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human

Tickers ADPT

December 06, 2025

From Io Therapeutics, Inc.

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

December 06, 2025

From Arvinas Inc.

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Tickers ARVN

December 06, 2025

From Beam Therapeutics

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

Tickers BEAM

December 06, 2025

From Aptose Biosciences, Inc.

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Tickers APTOF TSX:APS

December 06, 2025

From Disc Medicine Inc

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Tickers IRON

December 06, 2025

From Bicara Therapeutics Inc.

Cardinal Point Wealth Management Releases New 2025 Cross-Border Retirement Guide for High-Net-Worth Families

Tickers BCAX

December 06, 2025

From Cardinal Point Wealth Management, ULC

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

December 05, 2025

From Junshi Biosciences

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

December 05, 2025

From Cerevance, Inc.

Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

December 05, 2025

From Kirby McInerney LLP

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Tickers ANIK

December 05, 2025

From ORIC Pharmaceuticals

JHX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages James Hardie Industries plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – JHX

Tickers ORIC

December 05, 2025

AB Value Partners, L.P. Announces Proposed Settlement of Stockholder Class Action on Behalf of Former Holders of Orbit/FR, Inc. Common Stock - ORFR

Tickers JHX

December 05, 2025

From AB Value Partners LP

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SNPS

December 05, 2025

Webus International Limited Issues Clarification on Previous Announcement Related to Expedia Group

Tickers SNPS

December 05, 2025

From Webus International Limited

Sprouts Farmers Market, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the SFM Class Action

Tickers WETO

December 05, 2025

From Robbins LLP

OWL Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Blue Owl Capital Inc.

Tickers SFM

December 05, 2025

From Robbins LLP

BTDR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Bitdeer Technologies Group

Tickers OWL

December 05, 2025

From Robbins LLP

AVTR DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

Tickers BTDR

December 05, 2025

Tickers AVTR

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

December 05, 2025

From Clearmind Medicine Inc.